Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Communities across Nevada — from Alamo to smaller towns — are now accessing FDA-approved GLP-1 medications through licensed telehealth providers without leaving home. Your neighbors are getting results; you can too. Our NV-licensed physician network evaluates eligibility and prescribes the right GLP-1 medication for your community and your needs.
GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have transformed weight management for communities nationwide, with clinical trials showing 15-22% average body weight reduction. These same results are now available to every Nevada community through telehealth.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Nevada supports telehealth prescribing rights that allow licensed physicians to serve patients in every corner of the state — urban and rural alike. All NV-licensed providers in our network understand the local community healthcare landscape and comply with all applicable state and federal regulations.
Find your community below and connect with a local licensed GLP-1 provider. Every Nevada community has access.
GLP-1 receptor agonists are among the most rigorously studied obesity treatments, with evidence from placebo-controlled trials published in the New England Journal of Medicine:
Nevada authorizes board-certified licensed physicians to prescribe FDA-approved GLP-1 medications via telehealth after a valid patient-physician relationship is established through an online consultation. GLP-1 receptor agonists are not DEA-scheduled controlled substances — no in-person visit is legally required in Nevada.
Our telehealth network connects communities across Nevada and its neighboring states — providing access wherever you live.
Licensed telehealth GLP-1 care is available statewide. Select a city to begin your clinical assessment with a state-licensed, board-certified physician.
Local weight loss and GLP-1 providers serving the Nevada area, based on Google Business listings.
9017 S Pecos Rd %234425, Henderson, NV 89074
(702) 988-9616
5/5 ★ (51 reviews)
Visit website →180 W Huffaker Ln %23306, Reno, NV 89511
(775) 399-6577
4.9/5 ★ (207 reviews)
Visit website →6930 S Cimarron Rd %23220, Las Vegas, NV 89113
(702) 822-7400
4.9/5 ★ (380 reviews)
Visit website →Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes, in every community across Nevada — from the largest cities to small towns. Our network of NV-licensed telehealth physicians provides GLP-1 prescribing access to all residents, regardless of where they live in the state.
Every Nevada community can access the full range of FDA-approved GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — through telehealth, the same medications available at specialist clinics in large cities.
Medication delivery through licensed US pharmacies reaches every Nevada address — urban or rural. After consultation and prescription approval, your GLP-1 medication typically ships within 24-48 hours and arrives within 3-5 business days, no matter where in Nevada you live.
All physicians in our network hold active NV medical licenses and are familiar with Nevada healthcare regulations, local coverage options, and community health needs. They prescribe within full compliance of all applicable state laws and regulations.
Yes. GLP-1 telehealth has grown rapidly across Nevada communities. Patients in large cities and small towns alike are achieving 15-22% average body weight reduction through online consultations and home delivery. The community is already embracing this accessible approach to weight management.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
